Table 3 Secondary outcomes.

From: A randomised controlled trial of plasma exchange compared to standard of care in the treatment of severe COVID-19 infection (COVIPLEX)

 

SoC (n = 11)

PLEX (n = 11)

p-value

Serious adverse events

1

0

> 0.999

Requirement for IMV

 28 days

4 (36%)

6 (55%)

0.670

Time to IMV (days)

3 (-4 to 6)

5 (1–9)

0.224

Requirement for ECMO

 28 days

1 (9%)

1 (9%)

 > 0.999

Requirement for RRT

 28 days

1 (9%)

3 (27%)

0.587

Time to RRT (days)

18

12 (8–14)

–

Mortality

 28 days

1/11 (9%)

2/11 (18%)

 > 0.999

  1. IMV invasive mechanical ventilation, ECMO extracorporeal membrane oxygenation, RRT renal replacement therapy, PEX plasma exchange, SoC standard of care.
Back to article page